///Symposium: Implementing single low dose primaquine for transmission-blocking in sub-Saharan Africa: where do we stand & where are we going to counter the new threat of artemisinin partial resistance?

Symposium: Implementing single low dose primaquine for transmission-blocking in sub-Saharan Africa: where do we stand & where are we going to counter the new threat of artemisinin partial resistance?

When: Monday 22 April 2024, 10:30-12:00 (CAT)
Where: Kigali Convention Centre, Room AD11
Organiser: University of Oxford (UK)

The theme of this symposium is the role of single low-dose primaquine (SLDPQ) as a tool within a broader strategy to eliminate artemisinin-resistant Plasmodium falciparum in sub-Saharan Africa. The team will present evidence and showcase their current activities to reassure control programmes of the merits of using SLDPQ.

EDCTP project(s) highlighted

  • DPP (funded by the EDCTP2 programme)
  • IMPRIMA (funded by the Global Health EDCTP3 programme)

Agenda


Coordinator: Bob Taylor, University of Oxford (UK)

Chairs:

  • Sodiomon B. Sirima, Groupe Action de Recherche en Santé (GRAS, Burkina Faso)
  • Riana Rakatosaona, Centre National d’Application de Recherche Pharmaceutique (CNARP, Madagascar)


Introduction

Views from NMCPs: Perspectives on single low-dose primaquine (SLDPQ) from the NMCP – what are we worried about and what more evidence we would like to see to deploy and counter ART-R?
Aimable Mbituyumuremyi, Rwanda Biomedical Center/Ministry of Health (Rwanda) and Pierre Sinarinzi, Programme national intégré de lutte contre le paludisme (PNILP, Burundi)

SLPDQ dosing: Do we finally have an evidence-based dose of SLDPQ we can recommend for Africa?
Bob Taylor, University of Oxford (UK)

PQ formulations: Getting flavoured, child-friendly primaquine into those that need it
Julie Nguyen Ngoc Pouplin, Réseau Médicaments et Développement (ReMeD, France)

The IMPRIMA study: Implementing SLDPQ in partnership with communities across Africa to build evidence in the real world
Riana Rakatosaona, Centre National d’Application de Recherche Pharmaceutique (CNARP, Madagascar)

Panel discussion

  • Didier Menard, University of Strasbourg (France)
  • Arsène Ratsimbasoa, Direction de la lutte contre les maladies infectieuses, Ministère de la santé, du planning familial et de la protection sociale du Madagascar (Madagascar)
  • Joseph Nyandwi of the Institut National de Santé Publique (Burundi)